Status:
ENROLLING_BY_INVITATION
PET/CT Imaging in COVID-19 Patients
Lead Sponsor:
University of California, Davis
Conditions:
COVID-19
SARS-CoV-2 Infection
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.
Detailed Description
The goal of the study is to to acquire 18F-αvβ6-BP PET/CT images in patients diagnosed with SARS CoV2 and to demonstrate the ability of 18F-αvβ6-BP to detect lung damage.
Eligibility Criteria
Inclusion
- Men and women age ≥ 18 yrs
- Diagnosed with SARS CoV2
- Must have 2 sequential COVID negative tests prior to each scan
- Must have no previous lung disease prior to SARS CoV2 infection
- Lung image (Xray or CT) taken during infectious/ diagnosis period
- Will sign the IRB-approved consent form
- Able to remain motionless for up to 30-60 minutes per scan.
Exclusion
- Life expectancy \<3 mo
- Women who are pregnant or breast-feeding
- Patients who cannot undergo PET/CT scanning because of weight limits(\>350lbs)
- Lack of availability for follow-up assessments
- Re-infection with SARS CoV2 between scan sessions
- Other active infectious respiratory illness
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04376593
Start Date
May 1 2020
End Date
June 1 2026
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Davis
Sacramento, California, United States, 95817